Alto Neuroscience (ANRO) Non-Current Assets (2023 - 2026)
Alto Neuroscience's (ANRO) quarterly Non-Current Assets came in at $7.1 million in Q1 2026, down 15.0% year-on-year from $8.4 million in Q1 2025, and up 2.32% quarter-over-quarter from $7.0 million in Q4 2025.
Alto Neuroscience (ANRO) Non-Current Assets (2023 - 2026) Analysis & Trends
Alto Neuroscience has disclosed Non-Current Assets across 4 years of filings, most recently posting $7.1 million for Q1 2026.
- Non-Current Assets for Q1 2026 came in at $7.1 million, down 15.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.7 million (up 11.52% YoY), and the FY2025 annual result was $7.0 million, down 15.04% from the prior year.
- Non-Current Assets came in at $7.1 million for Q1 2026 at Alto Neuroscience, up from $7.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $8.4 million in Q1 2025 to a low of $1.2 million in Q4 2023.
- The 4-year median for Non-Current Assets is $7.3 million (2025), against an average of $5.9 million.
- Across the five-year window, Non-Current Assets surged 563.3% in 2024 and retreated 15.04% in 2025, its largest moves.
- Alto Neuroscience's Non-Current Assets stood at $1.2 million in 2023, then soared by 563.3% to $8.2 million in 2024, then declined by 15.04% to $7.0 million in 2025, then gained by 2.32% to $7.1 million in 2026.
- The last three Non-Current Assets figures came in at $7.1 million (Q1 2026), $7.0 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 62,953.78 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 39.71 Mn |
| 10 | Alto Neuroscience | 643.06 Mn | 379.30 Mn | - | 7.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.13 Mn |
| Dec 31, 2025 | 6.97 Mn |
| Sep 30, 2025 | 7.56 Mn |
| Jun 30, 2025 | 8.03 Mn |
| Mar 31, 2025 | 8.39 Mn |
| Dec 31, 2024 | 8.21 Mn |
| Sep 30, 2024 | 8.08 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 1.24 Mn |